Hannah C. M. Schenk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hannah C. M. Schenk has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Dave L. Roelen
Department of Immunology Leiden University Medical Center Leiden The Netherlands
2 shared publications - Ilse Gille
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands
2 shared publications - Jordi Rovira
Nephrology and Transplantation (LENIT), Fundació Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain
2 shared publications - Sebastiaan Heidt
Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus Medical Center
2 shared publications Adam M. Bourke
Department of Pathology, University of Cambridge, Cambridge, UK
1 shared publication- Aiko P. J. de Vries
Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Open AccessChimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- Open Access
Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug
Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients. The scope of CAR T‐cell therapy has since expanded to various other applications. Recently, CD19‐directed CAR T cells have shown promising results in treating B‐cell‐mediated autoimmune diseases, with patients experiencing long‐lasting symptom cessation. Despite these advancements, the unselective targeting of both pathogenic and protective B cells calls for precise immunotherapies capable of selectively removing pathogenic B cells. Therefore, antigen‐specific CARs were designed to specifically interact with and deplete subpopulations of target cells expressing the target antigens. Subsequently, modified CARs were introduced by incorporating autoantigens into the sequence, which allowed antigen‐specific B cells to bind to CAR T cells. Additionally, antigen‐specific CAR T cells have been exploited to treat viral infections. Moreover, CAR technology was expanded to regulatory T cells (Tregs), where CARs can be adopted to induce a tolerogenic environment in target tissues, offering new possibilities in autoimmune diseases, as well as prevention of graft‐versus‐host disease in haematopoietic stem cell transplantation and transplant rejection in the setting of solid organ transplantation. Although CAR T cells and CAR Tregs are promising and broadly explored, safety issues must be addressed and possible solutions thoroughly investigated. This review outlines the broad potential of CAR‐based therapies in autoimmunity, virology and transplantation while addressing the need for solutions to current safety issues.
Open AccessChimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug
Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients. The scope of CAR T‐cell therapy has since expanded to various other applications. Recently, CD19‐directed CAR T cells have shown promising results in treating B‐cell‐mediated autoimmune diseases, with patients experiencing long‐lasting symptom cessation. Despite these advancements, the unselective targeting of both pathogenic and protective B cells calls for precise immunotherapies capable of selectively removing pathogenic B cells. Therefore, antigen‐specific CARs were designed to specifically interact with and deplete subpopulations of target cells expressing the target antigens. Subsequently, modified CARs were introduced by incorporating autoantigens into the sequence, which allowed antigen‐specific B cells to bind to CAR T cells. Additionally, antigen‐specific CAR T cells have been exploited to treat viral infections. Moreover, CAR technology was expanded to regulatory T cells (Tregs), where CARs can be adopted to induce a tolerogenic environment in target tissues, offering new possibilities in autoimmune diseases, as well as prevention of graft‐versus‐host disease in haematopoietic stem cell transplantation and transplant rejection in the setting of solid organ transplantation. Although CAR T cells and CAR Tregs are promising and broadly explored, safety issues must be addressed and possible solutions thoroughly investigated. This review outlines the broad potential of CAR‐based therapies in autoimmunity, virology and transplantation while addressing the need for solutions to current safety issues.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadq3066
Interactions between placental Hofbauer cells and L. monocytogenes change throughout gestation
Hofbauer cells (HBCs) are extraembryonic macrophages generated de novo within the human placenta. In this study, we explored how the properties of HBCs change throughout gestation. Our analysis revealed transcriptomic differences between first-trimester and term HBCs, with many of the altered genes linked to immune responses. As pregnancy progresses, HBCs exhibit a marked decrease in phagosome maturation and acidification. We show that the differences between first-trimester and term HBCs are important in the context of infection with Listeria monocytogenes , a pathogen that crosses the placenta and replicates within macrophages. Specifically, we observed reduced colony-forming units and diminished actin recruitment by L. monocytogenes in first-trimester HBCs compared with term HBCs. Our findings indicate that the ability of L. monocytogenes to escape from vacuoles is impaired within first-trimester HBCs. Thus, the changes in HBC biology across pregnancy are important in shaping their interactions with L. monocytogenes.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadq3066
Interactions between placental Hofbauer cells and L. monocytogenes change throughout gestation
Hofbauer cells (HBCs) are extraembryonic macrophages generated de novo within the human placenta. In this study, we explored how the properties of HBCs change throughout gestation. Our analysis revealed transcriptomic differences between first-trimester and term HBCs, with many of the altered genes linked to immune responses. As pregnancy progresses, HBCs exhibit a marked decrease in phagosome maturation and acidification. We show that the differences between first-trimester and term HBCs are important in the context of infection with Listeria monocytogenes , a pathogen that crosses the placenta and replicates within macrophages. Specifically, we observed reduced colony-forming units and diminished actin recruitment by L. monocytogenes in first-trimester HBCs compared with term HBCs. Our findings indicate that the ability of L. monocytogenes to escape from vacuoles is impaired within first-trimester HBCs. Thus, the changes in HBC biology across pregnancy are important in shaping their interactions with L. monocytogenes.